Market Research Industry Reports

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2018, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) (Womens Health) pipeline landscape.

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Womens Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Intraepithelial Neoplasia (CIN) (Womens Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 11, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 3 and 3 molecules, respectively.

Cervical Intraepithelial Neoplasia (CIN) (Womens Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) (Womens Health).
- The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Womens Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cervical Intraepithelial Neoplasia (CIN) (Womens Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cervical Intraepithelial Neoplasia (CIN) (Womens Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Womens Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Womens Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) (Womens Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cervical Intraepithelial Neoplasia (CIN) - Overview
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development
Bioleaders Corp
CEL-SCI Corp
Genexine Inc
Inovio Pharmaceuticals Inc
IRX Therapeutics Inc
PDS Biotechnology Corp
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
THEVAX Genetics Vaccine USA Inc
Transgene SA
Vaccibody AS
Vaxart Inc
Cervical Intraepithelial Neoplasia (CIN) - Drug Profiles
ABI-1968 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aminolevulinic acid hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSILSB-710c - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLBL-101c - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GX-188E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXI-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IRX-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Multikine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSC-721689 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PDS-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RKP-00156 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-4001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TVGV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target E7 for HPV Associated Cancers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-1016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VGX-3100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vvax-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products
Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones
Featured News & Press Releases
Feb 14, 2018: IRX Therapeutics Announces Initiation of Phase 2 Clinical Trial of IRX-2 in Squamous Cervical or Vulvar Intraepithelial Neoplasia 3
Dec 12, 2017: Vaccibody Announces Finalization of the Recruitment in the Phase IIa Part of Its Study With VB10.16 Immunotherapy for Patients With HPV16 Induced High Grade Lesions of the Cervix
Nov 29, 2017: Inovios Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy
Jun 21, 2017: Vaccibody Announces Positive Results From the 12-month Analysis of the Phase I Part of the Clinical Trial VB C-01 in Patients With High-grade Cervical Dysplasia
Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer
Mar 23, 2017: Vaccibody Announces Vaccination Of First Patient In Its Phase IIA Study With VB10.16 Immunotherapy For Patients With HPV16 Induced High Grade Lesions Of The Cervix
Mar 02, 2017: Vaccibody Announces Approval Of Amendment Of IMPD Allowing To Start Of Expansion Phase In Its Phase I/IIa Study With VB10.16 Immunotherapy For Patients With HPV16 Induced High Grade Lesions Of The Cervix
Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed
Jun 21, 2016: Genexine Presents Interim Clinical Data of GX-188E at EUROGIN 2016
Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as Best Therapeutic Vaccine by World Vaccine Congress
Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet
Apr 23, 2015: Global clinical development accelerated as cervical intraepithelial neoplasia therapeutic, GX-188E received expanded approval for Phase II from Europe
Mar 02, 2015: Genexines cervical intraepithelial neoplasia therapeutic "GX-188E" receives approval for Phase II in Europe
Jan 26, 2015: TheVax Genetics Vaccine Announces TVGV-1 Update
Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Bioleaders Corp, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by CEL-SCI Corp, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Genexine Inc, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by IRX Therapeutics Inc, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by PDS Biotechnology Corp, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Transgene SA, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaccibody AS, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaxart Inc, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, H1 2018
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, H1 2018

List Of Figures

List of Figures
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2018

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2018, provides an overview

USD 2000View Report

Cervical Cancer - Pipeline Review, H1 2018

Cervical Cancer - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H1 2018, provides an overview of the Cervical Cancer

USD 2000View Report

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2017

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2017, provides an overview

USD 2000View Report

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2016

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2016Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) Pipeline Review, H2 2016, provides an overview

USD 2000View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Jun 2018
No. of Pages :94
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube